Harrow Health Inc

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

HROW reaffirms 2023 guidance, emphasizes IHEEZO's commercial potential

HROW's Q1 earnings call highlighted the company's commitment to achieving its 5-year plan goals, successful product launches, and strategic focus on innovation and market expansion. The call also addressed challenges in managing the growing product portfolio and ensuring sustainable guidance.

Harrow expects strong revenue growth from new acquisitions and branded products

Harrow is confident in meeting 2023 financial guidance and expects immediate accretion to earnings from recent acquisitions. The company's revenue growth is driven by branded products, with a focus on VEVYE and IHEEZO. Discussions on lowering the leverage ratio and using debt for potential transactions were highlighted, along with a drop in net equity and subsequent capital raise.

Harrow Reports Record Revenues and Seeks Expansion Opportunities in Pharma

Harrow's Q3 performance showcased strong revenue growth and promising developments in product demand and marketing efforts. While facing challenges, the company remains confident in its prospects and is actively pursuing opportunities for growth and market expansion.

Harrow reports robust Q4 earnings, eyes growth opportunities in 2024

Harrow's Q4 2023 earnings call highlighted strong financial performance, successful product launches, and a positive outlook for future growth. Despite challenges such as a cyber attack and product reintroduction hurdles, the company remains confident in its ability to navigate these obstacles and continue on a growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 14, 2024, to discuss the.

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt's Series A Preferred Stock financing in 2019. The capital raised will primarily support the further developmen.

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

Harrow, Inc. (HROW) Q4 2023 Earnings Call Transcript

Harrow (NASDAQ: HROW ) stock is moving on Wednesday following the release of the eyecare pharmaceutical company's earnings report for the fourth quarter of 2023. The Harrow report starts with core earnings per share of -20 cents.

Why Is Harrow (HROW) Stock Down 7% Today?

Harrow (NASDAQ: HROW ) stock is moving on Wednesday following the release of the eyecare pharmaceutical company's earnings report for Q4 2023. The Harrow report starts with core earnings per share of -20 cents.

Why Is Harrow (HROW) Stock Up 5% Today?

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also posted its fourth quarter and year-end Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period as well.

Harrow Announces Fourth Quarter and Year-End 2023 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Wednesday,.

Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024

Harrow Inc. is leveraging its existing customer base in the compounded ophthalmic pharmaceutical products business to expand into branded pharmaceuticals. The company's first major branded drug, Iheezo, initially faced skepticism but has seen significant success, with December 2023 sales reaching an estimated $5 million, triple the November rate. The success of Iheezo suggests that Harrow's distribution platform and customer base can support the success of other branded drugs, potentially leading to a triple-digit share price.

Harrow's Drug Iheezo Is Off To A Great Start

NASHVILLE, Tenn. & TORONTO--(BUSINESS WIRE)---- $HROW--Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. (“Apotex”), Canada's largest pharmaceutical company, today jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter (OTC) Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®. “We are pleased to enter the Canadian.

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

Harrow has two outstanding notes on offer that come up for maturity in 2026 and 2027. The 11.875% Senior Notes due 2027 offer a compelling 11.5% yield on cost and trade at a just under 3% premium to their $25 per share liquidation value. Cash and equivalents of $65.61 million at the end of Harrow's most recent quarter have been declining, and the company is not yet GAAP profitable.

Harrow: Hedge Downside Risk With The 11.5% Yielding Baby Bonds

Harrow, Inc.'s stock price has fallen due to disappointing earnings releases in Q1, Q2, and Q3 of 2023. The company's various revenue buckets have not performed as well as expected, leading to a decline in revenue.

Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to the Company's Board of Directors, effective immediately. Harrow's Board now consists of six members. “I am delighted to announce the addition of Adrienne and Lauren as new members to the Harrow Board of Directors,” said Mark L. Baum, Chairman and Chief Executive Officer of Harrow. “Having served in senior ex.

Harrow Announces New Appointments to its Board of Directors

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) dosed prescription drug based on a “water‑free” semifluorinated alkane eyedrop technology, is now available in the U.S. – and includes a 100% Money‑Back Guarantee program. VEVYE, uniquely dispensed in a 10 microliter drop, is the first and only cyclosporine‑based product indicate.

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has partnered with three leading healthcare technology platforms to expand U.S. availability of VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) dosed, ophthalmic solution prescription drug based on a “water-free” semifluorinated alkane (SFA) eyedrop technology. VEVYE, uniquely dispensed in a 10 microliter drop, is the first.

Harrow Partners with Leading Healthcare Market Access Technology Platforms

Arrival Group

Bank of Hawaii

Omeros

PAR Technology

Theravance Biopharma

Trupanion

While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it's time to address this speculative practice under a three-dimensional lens.

7 Short-Squeeze Stocks That Are Screaming for Speculation

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy.

Harrow Completes Transfer of the TRIESENCE® New Drug Application

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the following two upcoming conferences: BTIG 3rd Annual Ophthalmology Day Format: Fireside Chat (Virtual) Date/Time: Monday, November 27, 2023, at 1:30 p.m. ET Piper Sandler 35th Annual Healthcare Conference (The Lotte New York Palace, New York, NY) Format: Fireside Chat.

Harrow to Present at Two Investor Conferences in November

Akzo Nobel NV

Garrett Motion

AKZOY, GTX and HROW have been added to the Zacks Rank #5 (Strong Sell) List on November 14, 2023.

New Strong Sell Stocks for November 14th

Harrow, Inc. (NASDAQ:HROW ) Q3 2023 Earnings Conference Call November 13, 2023 4:45 PM ET Corporate Participants Jamie Webb - Director-Communications & Investor Relations Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann Mayank Mamtani - B. Riley Operator Good afternoon, and welcome to Harrow's Third Quarter 2023 Earnings Conference Call.

Harrow, Inc. (HROW) Q3 2023 Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2023. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period as well as the.

Harrow Announces Third Quarter 2023 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provi.

Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for the following products: FLAREX® (fluorometholone acetate ophthalmic suspension) 0.1%, a corticosteroid indicated for use in the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. NATACYN® (natamycin ophthalmic.

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

Harrow has provided long-term revenue guidance of $1B in 2027. If they deliver on this, the shares are likely to head north of $100. Perhaps a lot north. In order to deliver as promised, Harrow needs to succeed in its bold move into branded pharmaceutical products. Investors are looking for any signs of how well that's going. In this article, I examine the data we have so far and conclude that the early signs, while far from definitive, are good.

Implications Of Harrow's Short-Term Guidance

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from “Harrow Health, Inc.” to “Harrow, Inc.” to align with the Company's current five-year strategic plan, which includes an exclusive focus on eyecare pharmaceuticals. “Given the growing recognition of the Harrow name within the ophthalmic community, along with the connection of the Harrow brand to what is now one of the larg.

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.

Harrow Health has guided to at least $1 billion in revenue by 2027 based on their current portfolio of drugs. The company's deep moat and strong customer relationships make it possible for them to acquire valuable drugs and generate extraordinary returns. If Harrow Health achieves their revenue target, the stock price could reach $200 per share.

News for Harrow Health Inc Stock (HROW)